18F-氟雌二醇PET/CT在雌激素受体阳性乳腺癌中的诊断效能:组织病理学的关键作用——来自国际多中心前瞻性研究的证据
该国际多中心前瞻性研究纳入92例转移性乳腺癌患者(共2678处转移灶),对比18F-FES PET/CT与18F-FDG PET/CT的病灶检出率。患者水平分析中18F-FDG检出率97%高于18F-FES的86%(p=0.018);病灶水平分析中18F-FES在淋巴结、骨、肺和软组织比18F-FDG更敏感(p<0.01),且这种更高敏感性与小叶组织学相关。
要点
- 患者水平分析中18F-FDG PET/CT检出率97%高于18F-FES PET/CT的86%(p=0.018)。
- 病灶水平分析中18F-FES在淋巴结、骨、肺和软组织比18F-FDG更敏感(p<0.01)。
- 18F-FES更高敏感性与小叶组织学相关,患者水平OR 3.4(95%CI 1.0-12.3)。
核心结论
- 18F-FES PET/CT在患者水平的总检出率似乎低于18F-FDG PET/CT。
- 但18F-FES方法若为阳性,在大多数部位可识别出比18F-FDG更多的病灶。
- 18F-FES PET/CT的更高敏感性与小叶组织学相关。
研究设计与样本
- 来自多中心数据库,纳入所有同时接受18F-FES PET/CT和18F-FDG PET/CT的转移性乳腺癌患者。
- 两名阅片者独立评估两种图像,采用患者水平分析和病灶水平分析计算检出率。
- 使用多变量模型检验病理相关和临床因素作为18F-FES PET/CT优势的预测因素。
主要发现
- 共纳入92例患者,携带2678处转移灶。
- 患者水平分析中,18F-FDG与18F-FES PET/CT的检出率分别为97%和86%(p=0.018)。
- 病灶水平分析中,18F-FES方法在淋巴结、骨、肺和软组织比18F-FDG PET/CT更敏感(p<0.01)。
- 更高敏感性与小叶组织学相关:患者水平OR 3.4(95%CI 1.0-12.3)。
- 病灶水平分析中小叶组织学与更高敏感性相关:淋巴结转移OR 4.4(95%CI 1.2-16.1),骨病灶OR 3.29(95%CI 1.1-10.2)。
关键数值与推荐
- 患者水平检出率:18F-FDG PET/CT 97% vs 18F-FES PET/CT 86%(p=0.018)。
- 病灶水平分析中18F-FES在淋巴结、骨、肺和软组织比18F-FDG更敏感(p<0.01)。
- 小叶组织学预测18F-FES优势:患者水平OR 3.4(95%CI 1.0-12.3)。
- 小叶组织学预测18F-FES优势:淋巴结转移OR 4.4(95%CI 1.2-16.1)。
- 小叶组织学预测18F-FES优势:骨病灶OR 3.29(95%CI 1.1-10.2)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: [18F]Fluoroestradiol ([18F]FES) PET/CT has been proposed as a tool for detecting the oestrogen receptor density in patients with metastatic breast cancer (BC) non-invasively across all disease localizations. However, its diagnostic potential in terms of the detection rate (DR) of metastases is unclear. In this study, we pitted this method against [18F]FDG PET/CT and tried to identify predictors of the diagnostic superiority of the [18F] FES-based method. MATERIALS AND METHODS: From a multicentre database, we enrolled all patients with metastatic BC who had undergone both [18F]FES PET/CT and [18F]FDG PET/CT. Two readers assessed both images independently and used a patient-based (PBA) and lesion-based analysis (LBA) to calculate the DR. Pathology-related and clinical factors were tested as predictors of [18F]FES PET/CT superiority using a multivariate model. RESULTS: 92 patients, bearing a total of 2678 metastases, were enrolled. On PBA, the DR of [18F]FDG and [18F]FES PET/CT was 97% and 86%, respectively (p = 0.018). On LBA, the [18F]FES method proved more sensitive than [18F]FDG PET/CT in lymph nodes, bone, lung and soft tissue (p < 0.01). This greater sensitivity was associated with lobular histology, both on PBA (Odds Ratio (OR) 3.4, 95%CI 1.0-12.3) and on LBA (OR 4.4, 95%CI 1.2-16.1 for lymph node metastases and OR 3.29, 95%CI 1.1-10.2 for bone localizations). CONCLUSIONS: The overall DR of [18F]FES PET/CT appears to be lower than that of [18F]FDG PET/CT on PBA. However, the [18F]FES method, if positive, can identify more lesions than [18F]FDG at most sites. The higher sensitivity of [18F]FES PET/CT was associated with lobular histology.
引用
- Bottoni G, Fiz F, Puntoni M, et al. Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study. Eur J Nucl Med Mol Imaging. 2023. PMID: 36879065. doi:10.1007/s00259-023-06173-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。